Resources
12 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 12/15/2020 (updated 4/3/2024)
The presenter reviewed considerations in engaging and treating individuals with stimulant use disorders and presented evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 2/24/2021 (updated 4/4/2024)
This webinar provided new information on the risks and clinical challenges presented by individuals who use psychostimulants (cocaine, methamphetamine and prescription stimulants). A review of the clinical strategies that are important in working with this population were presented, including psychosocial and medication treatments for those with stimulant use disorder. Presented by Richard Rawson, Ph.D.
Posted 3/25/2021 (updated 4/5/2024)
Effective Harm Reduction Strategies for People Who Actively Use Opioids and/or Psychostimulants
Participants will learn evidenced-based harm reduction strategies to keep people who use opioids and psychostimulants alive with reduced disease burden. Presenters will discuss methods of engaging people who actively use opioids and/or psychostimulants, harm reduction interventions, overdose prevention and response, overamping prevention and response, and linkages to care.
Posted 5/3/2021 (updated 4/10/2024)
Building on Part I of the stigma webinar series and its introduction of a statewide collective impact model for addressing stigma, this webinar delivered the first part of the model that also served as its conceptual framework. This webinar introduced the stages of change and showed grantees how these apply to their target populations. We also discussed how those same principles applied to grantee engagement of community stakeholders and their openness to evidence-based practices that reduce morbidity and mortality related to SUD/OUD.
Posted 8/4/2021 (updated 4/2/2024)
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 2/11/2022 (updated 4/11/2024)
This packet presents Implementation III grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 4/12/2022 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, had five sessions of the Data Learning Collaborative (LC).
Posted 11/11/2022 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, created the 2022-2023 RCORP-TA Data Learning Collaborative (LC) for grantees to come together and share knowledge, talk through challenges, and build relationships with one another. This LC will build upon the foundation established in the prior 2022 RCORP-TA Data Learning Collaborative.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.